Placebo for Atogepant Clinical Trials
3 recruitingDrug
Phase 33
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
AbbVie420 enrolled61 locationsNCT06810505
Recruiting
Phase 3
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Migraine
AbbVie1,300 enrolled149 locationsNCT06241313
Recruiting
Phase 3
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Menstrual Migraine (MM)
AbbVie430 enrolled95 locationsNCT06806293